
## Sandrine Aspeslagh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/765158/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise. Nature Reviews Clinical Oncology, 2020, 17, 91-107.	27.6	283
2	Rationale for anti-OX40 cancer immunotherapy. European Journal of Cancer, 2016, 52, 50-66.	2.8	264
3	Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. European Journal of Endocrinology, 2019, 181, 363-374.	3.7	154
4	Pharmacological sensitivity of ATP release triggered by photoliberation of inositol-1,4,5-trisphosphate and zero extracellular calcium in brain endothelial cells. Journal of Cellular Physiology, 2003, 197, 205-213.	4.1	104
5	Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. EMBO Journal, 2011, 30, 2294-2305.	7.8	98
6	Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research, 2019, 25, 946-956.	7.0	96
7	Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer. Oncotarget, 2017, 8, 80443-80452.	1.8	78
8	Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Annals of Oncology, 2018, 29, 812-824.	1.2	73
9	TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?. Head and Neck Pathology, 2017, 11, 354-363.	2.6	67
10	Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?. Current Opinion in Oncology, 2019, 31, 54-64.	2.4	66
11	Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. ESMO Open, 2020, 5, e000947.	4.5	63
12	Cancer immunotherapy-associated hypophysitis. Seminars in Oncology, 2018, 45, 181-186.	2.2	47
13	PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. BMC Cancer, 2019, 19, 506.	2.6	46
14	Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes. Pathology, 2017, 49, 397-404.	0.6	43
15	NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. Oncolmmunology, 2017, 6, e1137418.	4.6	42
16	Activated iNKT Cells Promote Memory CD8+ T Cell Differentiation during Viral Infection. PLoS ONE, 2012, 7, e37991.	2.5	38
17	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. Oral Oncology, 2017, 70, 34-42.	1.5	38
18	Enhanced TCR Footprint by a Novel Glycolipid Increases NKT-Dependent Tumor Protection. Journal of Immunology, 2013, 191, 2916-2925.	0.8	37

#	Article	IF	CITATIONS
19	Importance of choice of materials and methods in <scp>PD</scp> â€L1 and <scp>TIL</scp> assessment in oropharyngeal squamous cell carcinoma. Histopathology, 2018, 73, 500-509.	2.9	37
20	Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?. European Journal of Endocrinology, 2021, 184, K1-K5.	3.7	37
21	Bacterial CD1d–Restricted Glycolipids Induce IL-10 Production by Human Regulatory T Cells upon Cross-Talk with Invariant NKT Cells. Journal of Immunology, 2013, 191, 2174-2183.	0.8	29
22	Divergent synthetic approach to 6′′-modified α-GalCer analogues. Organic and Biomolecular Chemistry, 2011, 9, 8413.	2.8	25
23	Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2017, 79, 1257-1265.	2.3	25
24	<i>JAK</i> Mutations as Escape Mechanisms to Anti–PD-1 Therapy. Cancer Discovery, 2017, 7, 128-130.	9.4	24
25	Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model. PLoS ONE, 2013, 8, e65075.	2.5	24
26	CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck. Pathobiology, 2016, 83, 327-333.	3.8	23
27	In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?. European Journal of Cancer, 2017, 87, 65-74.	2.8	19
28	Invariant natural killer T cells in rheumatic disease: a joint dilemma. Nature Reviews Rheumatology, 2010, 6, 90-98.	8.0	15
29	Synthesis and Evaluation of Amino-Modified α-GalCer Analogues. Organic Letters, 2010, 12, 2928-2931.	4.6	14
30	Synthesis of 6″-triazole-substituted α-GalCer analogues as potent iNKT cell stimulating ligands. Bioorganic and Medicinal Chemistry, 2012, 20, 7149-7154.	3.0	14
31	Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists. Bioorganic and Medicinal Chemistry, 2015, 23, 3175-3182.	3.0	14
32	C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. Melanoma Research, 2021, 31, 371-377.	1.2	12
33	Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. Anti-Cancer Drugs, 2017, 28, 341-349.	1.4	10
34	Bilateral Corneal Perforation in a Patient Under Anti-PD1 Therapy. Cornea, 2021, 40, 245-247.	1.7	10
35	Understanding genetic determinants of resistance to immune checkpoint blockers. Seminars in Cancer Biology, 2020, 65, 123-139.	9.6	9
36	Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor. Journal of Thoracic Oncology, 2016, 11, e21-e23.	1.1	8

SANDRINE ASPESLAGH

#	Article	IF	CITATIONS
37	Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors. Anti-Cancer Drugs, 2016, 27, 1021-1027.	1.4	7
38	A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder. Case Reports in Oncology, 2021, 14, 861-867.	0.7	7
39	Treatment duration of checkpoint inhibitors for NSCLC. Lancet Respiratory Medicine,the, 2019, 7, 835-837.	10.7	6
40	Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?. Journal of Thoracic Oncology, 2019, 14, 1701-1703.	1.1	6
41	Pneumocystis Infection in Two Patients Treated with Both Immune Checkpoint Inhibitor and Corticoids. Journal of Immunotherapy and Precision Oncology, 2020, 3, 27-30.	1.4	6
42	An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma. Melanoma Research, 2020, 30, 524-527.	1.2	5
43	Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors. Chinese Clinical Oncology, 2015, 4, 48.	1.2	5
44	Eosinophilic Fasciitis in a Patient Treated by Atezolizumab for Metastatic Triple-Negative Breast Cancer. Journal of Immunotherapy and Precision Oncology, 2019, 2, 101-105.	1.4	5
45	Are phase I trials safe for older patients?. Journal of Geriatric Oncology, 2018, 9, 87-92.	1.0	4
46	An In Silico Approach for Modelling T-Helper Polarizing iNKT Cell Agonists. PLoS ONE, 2014, 9, e87000.	2.5	4
47	Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy. Melanoma Research, 2021, 31, 272-276.	1.2	3
48	How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?. Current Opinion in Oncology, 2019, 31, 420-423.	2.4	2
49	Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade. Acta Clinica Belgica, 2021, 76, 144-148.	1.2	2
50	Preclinical Evaluation of Invariant Natural Killer T-Cells in the 5T33 Multiple Myeloma Model. Blood, 2012, 120, 938-938.	1.4	0